Entheon Biomedical (ENBI) AI Stock Analysis

• Market Cap: C$1.39M
• Dividend Yield: N/A
• Average Volume (3M): 7.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.75
• Revenue Growth: N/A
• EPS Growth: 34.22%
• Country: CA
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 13,858,926
• 10 Day Avg. Volume: 17,012
• 30 Day Avg. Volume: 7,955
• PEG Ratio: 0.18
• Price to Book (P/B): 7.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.10 ▼(-1.00% Downside)

The score is primarily held back by very weak financial performance (minimal revenue, ongoing losses, and cash burn despite no debt). Technicals are only mildly supportive with a short-term rebound but the stock remains below its 200-day average. The transformative acquisition/pivot provides potential upside but carries significant execution and dilution/approval risk, and valuation support is limited given losses and no dividend.

Entheon Biomedical Business Overview & Revenue Model

Company Description

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.

How the Company Makes Money

Entheon Biomedical generates revenue through a combination of research and development partnerships, licensing agreements, and potentially from future commercialization of therapeutic products. The company invests in clinical trials and scientific research to develop proprietary treatment protocols and compounds. Revenue streams may include collaborations with academic institutions, pharmaceutical companies, and healthcare providers, as well as potential government grants or funding for research in the mental health sector. Additionally, Entheon might seek monetization through intellectual property licensing once their psychedelic therapies are clinically validated and receive regulatory approval.

Entheon Biomedical Financial Statement Overview

Summary

Financials remain very weak with minimal/zero revenue and continued operating/net losses. Cash flow is negative with ongoing cash burn, increasing dilution/financing risk. The main offset is no reported debt, which limits balance-sheet stress.

Income Statement

Results remain very weak: the company is generating little to no revenue in the latest periods (including TTM (Trailing-Twelve-Months)) and continues to post operating and net losses. Losses have narrowed substantially versus the very large deficit in 2021–2022, but profitability is still not established and revenue visibility looks limited given the return to zero revenue in 2024 and TTM.

Balance Sheet

The balance sheet is conservatively levered with no debt reported, which reduces financial risk. However, equity has been volatile and materially lower than earlier years, and returns on equity are consistently negative—signaling ongoing value erosion until the business reaches sustainable profitability.

Cash Flow

Cash generation remains a key pressure point: operating cash flow and free cash flow are negative across periods, including TTM (Trailing-Twelve-Months), implying continued cash burn to fund operations. While cash burn is far smaller than the peak outflows seen in 2021–2022, the latest free cash flow trend is again deteriorating (TTM decline), keeping financing needs elevated.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	250.32K	189.68K	21.67K	0.00
Gross Profit	0.00	0.00	250.32K	189.68K	9.13K	-2.72K
EBITDA	-298.79K	-318.00K	13.99K	-3.60M	-8.21M	-1.64M
Net Income	-343.40K	-318.00K	-300.00K	-8.52M	-8.89M	-4.38M
Balance Sheet
Total Assets	407.46K	185.14K	401.08K	769.22K	9.98M	4.47M
Cash, Cash Equivalents and Short-Term Investments	382.21K	136.49K	344.63K	680.17K	2.05M	2.84M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	18.42K	39.81K	85.33K	154.65K	927.71K	728.19K
Stockholders Equity	389.04K	145.33K	315.75K	614.57K	9.05M	3.74M
Cash Flow
Free Cash Flow	-346.39K	-355.64K	-359.93K	-1.95M	-5.71M	-2.85M
Operating Cash Flow	-346.39K	-355.64K	-359.93K	-1.95M	-5.62M	-2.84M
Investing Cash Flow	0.00	0.00	24.40K	585.64K	-98.87K	1.08M
Financing Cash Flow	500.00K	147.50K	0.00	0.00	4.98M	4.43M

Entheon Biomedical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ENBI, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ENBI.

Entheon Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-3.36	-107.76%	―	―	34.22%
BETR	43 Neutral	C$7.59M	-3.76	―	―	―	62.43%

Entheon Biomedical Corporate Events

Entheon to Pivot into Nutraceuticals with $40 Million Nutravisor Acquisition

Entheon Biomedical has signed a binding letter of intent to acquire all of the issued and outstanding shares of Nutravisor Inc., after which the combined entity will continue Nutravisor’s business of pouch and nutraceutical consumer products. The deal, valued at approximately $40 million through the issuance of 53,333,333 Entheon shares at $0.75 on a post-consolidation basis, will see Entheon complete a roughly 6.93-for-1 share consolidation, shift control of management and the board to Nutravisor’s nominees, change its name, and undergo a fundamental change of business subject to regulatory, shareholder, and Canadian Securities Exchange approvals; trading in Entheon’s shares is expected to be halted while the transaction is reviewed and Nutravisor may raise up to $5 million via a concurrent private placement.